Literature DB >> 17178793

Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.

Perparim Kamberi1, Raymond A Sobel, Karl V Clemons, Andreas Waldvogel, Joan M Striebel, Paul L Williams, David A Stevens.   

Abstract

Coccidioidal meningitis (CM) is a devastating disease that requires long-term therapy and for which there is little hope of a cure. A model was used to compare the efficacies of itraconazole and fluconazole. CD-1 mice were infected intrathecally with 30 to 36 viable arthroconidia of Coccidioides. Oral therapy with cyclodextrin (control) or itraconazole or fluconazole at 10, 25, or 50 mg/kg of body weight twice daily (BID) was given for 12 days, from day 3 of infection. Treatment with both antifungals at all doses prolonged survival compared with that of the control treatment (P < 0.01 to 0.0001). At 50 mg/kg, itraconazole and fluconazole were equivalent, whereas itraconazole at 10 or 25 mg/kg prolonged survival compared to that achieved with fluconazole at these dosages (P < 0.05 and 0.01, respectively). Early histologic analysis (10 days of treatment) with 50 mg/kg BID itraconazole or fluconazole showed suppression of CM in all five animals per group; in quantitative cultures, three of three animals from each group had no detectable infection in the brain, spinal cord, or a site of secondary infection, the lungs. In contrast, four of seven controls showed mild to severe meningitis, with arteritis detected in three animals. In a short-term organ clearance study, 5 days of treatment with 10 or 50 mg/kg BID itraconazole or fluconazole reduced the tissue burdens in the brain and spinal cord compared to the tissue burdens in the controls (P < 0.02 to 0.0003). Fluconazole at 10 mg/kg did not reduce the fungal burden in secondary sites, the lungs and kidneys, whereas this itraconazole dose was more effective in clearing the fungi from both organs (P < 0.05 and P < 0.001, respectively). At 50 mg/kg, itraconazole and fluconazole were equivalent in clearing the fungi from the brain and kidney, but itraconazole was superior to fluconazole in clearing the fungi from the spinal cord and lungs (P < 0.05). Thus, both itraconazole and fluconazole were effective at controlling CM, but neither eliminated Coccidioides from tissues. Overall, itraconazole was more efficacious on an mg/kg basis; at high doses they were similarly effective.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178793      PMCID: PMC1803148          DOI: 10.1128/AAC.00332-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  Worst-rank score analysis with informatively missing observations in clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1999-10

2.  Pharmacokinetics of itraconazole following oral administration to normal volunteers.

Authors:  T C Hardin; J R Graybill; R Fetchick; R Woestenborghs; M G Rinaldi; J G Kuhn
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

Authors:  C A Arndt; T J Walsh; C L McCully; F M Balis; P A Pizzo; D G Poplack
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

Review 4.  Intrathecal amphotericin in the management of coccidioidal meningitis.

Authors:  D A Stevens; S A Shatsky
Journal:  Semin Respir Infect       Date:  2001-12

5.  Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis.

Authors:  J E Lutz; K V Clemons; B H Aristizabal; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 6.  Coccidioidomycosis.

Authors:  D A Stevens
Journal:  N Engl J Med       Date:  1995-04-20       Impact factor: 91.245

Review 7.  [Fluconazole in meningeal coccidioidomycosis].

Authors:  J J Ayala-Gaytán; B A Condarco-Cortés; J A Pérez-Zuno; P Moreno-Guevara
Journal:  Rev Invest Clin       Date:  1997 May-Jun       Impact factor: 1.451

8.  Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis.

Authors:  K N Sorensen; R A Sobel; K V Clemons; D Pappagianis; D A Stevens; P L Williams
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

9.  Treatment of coccidioidal meningitis with fluconazole.

Authors:  R M Tucker; J N Galgiani; D W Denning; L H Hanson; J R Graybill; K Sharkey; M R Eckman; C Salemi; R Libke; R A Klein
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

Review 10.  Pharmacokinetics of oral antifungals and their clinical implications.

Authors:  J Heykants; A Van Peer; K Lavrijsen; W Meuldermans; R Woestenborghs; G Cauwenbergh
Journal:  Br J Clin Pract Suppl       Date:  1990-09
View more
  7 in total

1.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

2.  Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease.

Authors:  George R Thompson; David A Stevens; Karl V Clemons; Josh Fierer; Royce H Johnson; Jane Sykes; George Rutherford; Michael Peterson; John W Taylor; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2014-10-16       Impact factor: 2.574

3.  Central nervous system paracoccidioidomycosis in an AIDS patient: case report.

Authors:  Mario León Silva-Vergara; Ivonete Helena Rocha; Rakel Rocha Vasconcelos; André Luiz Maltos; Fernando de Freitas Neves; Luciana de Almeida Silva Teixeira; Delio José Mora
Journal:  Mycopathologia       Date:  2014-01-24       Impact factor: 2.574

4.  Coccidioidal meningitis: update on epidemiology, clinical features, diagnosis, and management.

Authors:  Janis E Blair
Journal:  Curr Infect Dis Rep       Date:  2009-07       Impact factor: 3.725

5.  CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).

Authors:  Anjan Debnath; Claudia M Calvet; Gareth Jennings; Wenxu Zhou; Alexander Aksenov; Madeline R Luth; Ruben Abagyan; W David Nes; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2017-12-28

Review 6.  The Rise of Coccidioides: Forces Against the Dust Devil Unleashed.

Authors:  Marley C Caballero Van Dyke; George R Thompson; John N Galgiani; Bridget M Barker
Journal:  Front Immunol       Date:  2019-09-11       Impact factor: 7.561

7.  Nikkomycin Z against Disseminated Coccidioidomycosis in a Murine Model of Sustained-Release Dosing.

Authors:  Gabriele Sass; David J Larwood; Marife Martinez; Paulami Chatterjee; Melissa O Xavier; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.